Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Among the people who've received clemency in President Donald Trump’s second term are a pair of reality TV stars, a straw ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The Cancer Prevention and Research Institute of Texas has awarded nearly $3.4 million to UT Health San Antonio to advance ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

A Michigan lawmaker is hoping to give veterans a new way to treat post-traumatic stress disorder by decriminalizing ...

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...